We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $931M
1-Year Est. Return 41.63%
This Fund
S&P 500
This Quarter Est. Return
+16.83%
1 Year Est. Return
+41.63%
3 Year Est. Return
+181.18%
5 Year Est. Return
+113.34%
10 Year Est. Return
+1,823.73%
AUM
$2.49B
AUM Growth
+$21.6M
Cap. Flow
+$16.4M
Cap. Flow %
0.66%
Top 10 Hldgs %
58.42%
Holding
119
New
16
Increased
22
Reduced
16
Closed
17

Top Buys

Rank Stock Value
1
MORF
Morphic Holding, Inc. Common Stock
MORF
+$27.6M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$23.7M
3
GBT
Global Blood Therapeutics, Inc.
GBT
+$18.2M
4
MDCO
Medicines Co
MDCO
+$16M
5
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
+$14.8M

Top Sells

Rank Stock Value
1
NVDA icon
NVIDIA
NVDA
+$37M
2
AVTR icon
Avantor
AVTR
+$16.9M
3
Z icon
Zillow
Z
+$13.9M
4
BPMC
Blueprint Medicines
BPMC
+$13M
5
HTHT icon
Huazhu Hotels Group
HTHT
+$12.7M

Sector Composition

Rank Sector Weight
1 Healthcare 52.55%
2 Consumer Discretionary 26.12%
3 Miscellaneous 17.53%
4 Technology 2.9%
5 Communication Services 0.91%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
WW
1
DELISTED
WW International
WW
$560M 22.47%
14,818,300
– –
LXRX icon
2
Lexicon Pharmaceuticals
LXRX
$890M
$181M 7.27%
60,240,864
– –
BMY icon
3
CALL
Bristol-Myers Squibb
BMY
$130B
$177M 7.12%
3,500,000
+1,250,000
+56% +$58.7M
AVTR icon
4
Avantor
AVTR
$10B
$88.2M 3.54%
6,000,000
-1,000,000
-14% -$16.9M
BAC icon
5
CALL
Bank of America
BAC
$416B
$87.5M 3.51%
+3,000,000
New +$86.3M
ONC
6
BeOne Medicines Ltd
ONC
$39.2B
$79.6M 3.19%
650,000
– –
BABA icon
7
Alibaba
BABA
$272B
$75.3M 3.02%
450,000
– –
MRNA icon
8
Moderna
MRNA
$58.6B
$73.3M 2.94%
4,606,298
– –
MDCO
9
DELISTED
Medicines Co
MDCO
$70M 2.81%
1,400,000
+400,000
+40% +$16M
MS icon
10
CALL
Morgan Stanley
MS
$337B
$64M 2.57%
+1,500,000
New +$64.1M
XLRN
11
DELISTED
Acceleron Pharma
XLRN
$59.3M 2.38%
1,500,000
– –
ALNY icon
12
Alnylam Pharmaceuticals
ALNY
$33.5B
$56.3M 2.26%
700,000
+300,000
+75% +$23.7M
BPMC
13
DELISTED
Blueprint Medicines
BPMC
$44.1M 1.77%
600,000
-150,000
-20% -$13M
NVDA icon
14
NVIDIA
NVDA
$5.09T
$34.8M 1.4%
8,000,000
-8,800,000
-52% -$37M
MORF
15
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$32.9M 1.32%
1,819,186
+1,319,186
+264% +$27.6M
FATE icon
16
Fate Therapeutics
FATE
$277M
$31.1M 1.25%
2,000,000
+500,000
+33% +$9.58M
GOSS icon
17
Gossamer Bio
GOSS
$65.6M
$27M 1.08%
20,112
– –
ARGX icon
18
argenx
ARGX
$61.6B
$22.8M 0.91%
200,000
-20,000
-9% -$2.7M
RUBY
19
DELISTED
Rubius Therapeutics, Inc
RUBY
$22.2M 0.89%
2,833,791
– –
ATRA icon
20
Atara Biotherapeutics
ATRA
$94.2M
$21.2M 0.85%
60,000
+14,000
+30% +$5.22M
SAGE
21
DELISTED
Sage Therapeutics
SAGE
$21M 0.84%
150,000
– –
SRRK icon
22
Scholar Rock
SRRK
$6.75B
$21M 0.84%
2,346,040
– –
FOLD
23
DELISTED
Amicus Therapeutics
FOLD
$20.1M 0.8%
2,500,000
– –
Z icon
24
Zillow
Z
$7.31B
$19.4M 0.78%
650,000
-350,000
-35% -$13.9M
XBI icon
25
CALL
State Street SPDR S&P Biotech ETF
XBI
$10.6B
$19.1M 0.76%
+250,000
New +$20.8M
1
2 3 4 5

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $931M AUM 47.97% 1-Year Est. Return
ACM
Ashe Capital Management Englewood Cliffs, New Jersey $931M AUM 4.95% 1-Year Est. Return
SAM
Sycomore Asset Management Paris, France $932M AUM 51.25% 1-Year Est. Return
NS
Night Squared New York $930M AUM 56.46% 1-Year Est. Return
PA
Planning Alternatives Birmingham, Michigan $933M AUM 28.32% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $933M AUM 56.2% 1-Year Est. Return
CICI
Capital Investment Counsel Inc Raleigh, North Carolina $929M AUM 53.07% 1-Year Est. Return
CAM
Claret Asset Management Montreal, Quebec, Canada $928M AUM 25.4% 1-Year Est. Return

Artal Group's Q3 2019 Portfolio in Review

As of Q3 2019, Artal Group held 119 positions worth $2.49B, up 0.87% from $2.47B the previous quarter. Its ten largest holdings account for 58% of the portfolio.

Artal Group's Q3 2019 filing shows 16 new, 22 increased, 16 reduced and 17 closed positions. Its largest new stake was Global Blood Therapeutics, Inc.: 350,000 shares worth $17M. The largest sale was NVIDIA, an estimated $37M.

By sector, the portfolio is most concentrated in Healthcare at 53% of assets, down from 66% a quarter earlier, followed by Consumer Discretionary and Miscellaneous.

  • Artal Group's largest Q3 2019 buy was Global Blood Therapeutics, Inc.: 350,000 shares worth $17M.
  • Artal Group added most to Morphic Holding, Inc. Common Stock in Q3 2019, an estimated $27.6M increase.
  • Artal Group's biggest Q3 2019 reduction was NVIDIA, cutting an estimated $37M.
  • Artal Group fully exited Huazhu Hotels Group in Q3 2019, selling an estimated $12.7M.
  • Artal Group's ten largest holdings make up 58% of its $2.49B portfolio in Q3 2019.
  • Artal Group opened 16 new positions and closed 17 in Q3 2019.
  • Artal Group's portfolio value rose 0.87% quarter-over-quarter to $2.49B.

Based on Artal Group's 13F filing for Q3 2019, filed 14 Nov 2019.